Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: Higher incidence than previously thought

Otology and Neurotology

Volumn 26, Issue 1, 2005, Pages 93-97

  Evans, D Gareth R ^a   Moran, Anthony ^b   King, Andrew ^c   Saeed, S ^d,e   Gurusinghe, Nihal ^d,e   Ramsden, Richard ^d,e  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

Incidence; Mosaic; Mutations; NF2; Vestibular schwannoma

Indexed keywords

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; AGED; CANCER INCIDENCE; CANCER REGISTRY; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEURILEMOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; VESTIBULAR SCHWANNOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; ENGLAND; FEMALE; HOSPITAL RECORDS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOSAICISM; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; RISK;

EID: 12344281996     PISSN: 15317129     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129492-200501000-00016     Document Type: Review

References (25)

1. Tos M, Thomsen J. Epidemiology of acoustic neuromas. J Laryngol Otol 1984;98:685-92.
2. Moffat DA, Hardy DG, Baguley DM. Strategy and benefits of acoustic neuroma searching. J Laryngol Otol 1989;103:51-9.
3. Tos M, Charabi S, Thomsen J. Incidence of vestibular schwannomas. Laryngoscope 1999;109:736-40.
4. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-21.
5. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel Moesin-Ezrin-Radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;75:826.
6. Moyhuddin A, Neary WJ. Wallace A, et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 2002;39:315-22.
7. Evans DGR, Wallace A, Trueman L, et al. Mosaicism in classical neurofibromatosis type 2: a common mechanism for sporadic disease in tumor prone syndromes? Am J Hum Genet 1998;63: 727-36.
8. Moyhuddin A, Baser ME, Watson C, et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003;40:459-63.
9. Frohlich AM, Sutherland GR. Epidemiology and clinical features of vestibular schwannoma in Manitoba, Canada. Can J Neurol Sci 1993;20:126-30.
10. Lanser MJ, Sussman SA, Frazer K. Epidemiology, pathogenesis and genetics of acoustic tumors. Otolaryngol Clin North Am 1992; 25:499-520.
11. Joensen P. Incidence of primary intracranial neoplasms in an isolated population (Faroese) during the period 1962-1975. Acta Neurol Scand 1981;64:74-8.
12. Evans DGR, Blair V, Strachan T, et al. Variation in expression of the gene for type 2 neurofibromatosis: absence of a gender effect on vestibular schwannoma. J Otolaryngol 1995;109:830-5.
13. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the north west of England and the UK: 1. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-6.
14. Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
15. Baser ME, Friedman JM, Aeschilman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002; 71:715-23.
16. Kluwe L, Mautner VF, Heinrich B, et al. Molecular sudy of frequency of mosaicism in classical neurofibromatosis 2 patients. J Med Genet 2003;40:109-14
17. Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology 2001;56:1433-43.
18. Baser ME, Friedman JM, Wallace AJ, et al. Evaluation of diagnostic criteria for neurofibromatosis 2. Neurology 2002;59: 1759-65
19. Boum D, Carter SA, Mason S, Evans DGR, Strachan T. Germline mutations in the neurofibromatosis type 2 tumor suppressor gene. Hum Mol Genet 1994;3:813-6.
20. Merel P, Hoang-Xuan K, Sanson M, et al. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer 1995;12: 117-27.
21. Ruttledge MH, Andermann AA, Phelan CM, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-42.
22. Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59: 529-39.
23. Evans DGR, Trueman L, Wallace A, et al. Genotype/phenotype correlations in type 2 neurofibromatosis: evidence for more severe disease associated with truncating mutations. J Med Genet 1998; 35:450-5.
24. National Institutes of Health. National Institutes of Health consensus development conference statement on neurofibromatosis: Arch Neurol 1987;45:575-9.
25. Gutmann DH, Aylesworth A, Carey JC, et al. The diagnostic and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-7.